Clinical and Pathological Characteristics of BRCA2 Positive Breast Cancer in Egyptian Female PatientsClinical and Pathological Characteristics of BRCA2 Positive Breast Cancer in Egyptian Female PatientsMutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. Early age at ons...
产品名称 Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) 产品规格 50µg 200µg 1mg 5mg 有效成分含量 99% 是否进口 是 用途范围 Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白。 包装规格 0.5kg 来源 原核表达 片段与标签 Lys2308~His2537 ...
Vascular endothelial growth factor (VEGF) inhibition is a rational therapeutic approach in breast cancer because VEGF plays an important role in tumour blood vessel growth, tumour progression and metastasis. Bevacizumab is a recombinant humanised antibody targeted at VEGF. As VEGF is overexpressed in ...
BRCA2-mutated carriers have a high lifetime risk of breast cancer (BC), an early age of onset, and an increased risk of other cancers (including ovarian, pancreatic, and prostate cancer). Almost 70–80% of BRCA2-mutated BC are estrogen receptor (ER)-positive, which is a particular type...
中文名称:乳腺癌易感蛋白2(BRCA2)重组蛋白英文名称:Recombinant Breast Cancer Susceptibility Protein 2 (BRCA2) 保存条件:避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月纯度规格:> 95% 产品类别:重组蛋白 货号::BES20998RP 乳腺癌易感蛋白2(BRCA2)重组蛋白 ...
应用Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白 序列 用法 Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex. 储存 避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
[13] Byrski T, Dent R, Blecharz P, et al. Results of a phase Ⅱ open- label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer[ J]. Breast Cancer Res, 2012...
1.Byrski T, Huzarski T, Dent R, et al:Pathologic complete response to neoadjuvant cisplatin inBRCA1 positive breast cancer patients. Breast Cancer Res Treat 147:401-5, 2014 2.KaufmanB,ShapiraFrommer R, Schmutzler RK, et al: Olaparib m...
Angelina Jolie made major headlines earlier this year when she revealed that she'd tested positive for a faulty BRCA1 gene (which puts your odds of breast cancer at about 87 percent)—and had decided to get a double mastectomy because of it. Women with a family history of breast or ovaria...
Adjusting for grade, BRCA2-associated tumors were more often estrogen receptor positive (P=0.008) and exhibited a luminal phenotype (P=0.003). They were less likely than controls to express the basal cytokeratin CK5 (P=0.03) or to overexpress HER2/neu protein (P=0.06). There was no ...